Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has been assigned an average rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $5.31.
A number of brokerages have weighed in on OMED. Cantor Fitzgerald set a $6.00 price target on Oncomed Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, January 4th. Zacks Investment Research upgraded Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Thursday, January 4th. Finally, HC Wainwright reiterated a “hold” rating and set a $3.00 price target on shares of Oncomed Pharmaceuticals in a report on Friday, March 9th.
Shares of Oncomed Pharmaceuticals stock opened at $2.92 on Friday. Oncomed Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $9.54. The firm has a market capitalization of $111.72, a PE ratio of -2.81 and a beta of 2.18.
Several institutional investors and hedge funds have recently modified their holdings of the company. Endurant Capital Management LP acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter valued at about $570,000. Crestline Management LP acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter valued at about $753,000. Millennium Management LLC grew its stake in shares of Oncomed Pharmaceuticals by 148.7% in the 4th quarter. Millennium Management LLC now owns 543,335 shares of the biopharmaceutical company’s stock valued at $2,228,000 after buying an additional 324,845 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter valued at about $135,000. Finally, Perceptive Advisors LLC grew its stake in shares of Oncomed Pharmaceuticals by 152.4% in the 4th quarter. Perceptive Advisors LLC now owns 2,620,897 shares of the biopharmaceutical company’s stock valued at $10,745,000 after buying an additional 1,582,608 shares during the period. Institutional investors own 53.47% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Oncomed Pharmaceuticals Inc (OMED) Receives Average Rating of “Hold” from Analysts” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3298847/oncomed-pharmaceuticals-inc-omed-receives-average-rating-of-hold-from-analysts.html.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.